已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies

路易氏体型失智症 认知功能衰退 痴呆 联想(心理学) 医学 内科学 疾病 心理学 心理治疗师
作者
Maria Camila González,Nicholas James Ashton,Bárbara Fernandes Gomes,Diego Tovar,Frédéric Blanc,Thomas K. Karikari,Brit Mollenhauer,Andrea Pilotto,Afina Willemina Lemstra,Claire Paquet,Carla Abdelnour Ruiz,Milica Gregorič Kramberger,Laura Bonanni,Rik R. Vandenberghe,Abdul Hye,Kaj Blennow,Henrik Zetterberg,Dag Aarsland,Claudia Carrarini,Mirella Russo
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:79 (1): 32-32 被引量:99
标识
DOI:10.1001/jamaneurol.2021.4222
摘要

Importance: Plasma phosphorylated tau (p-tau) has proven to be an accurate biomarker for Alzheimer disease (AD) pathologic characteristics, offering a less expensive and less invasive alternative to cerebrospinal fluid (CSF) and positron emission tomography biomarkers for amyloid-β and tau. Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder. Objective: To measure the concentrations of plasma p-tau (p-tau181 and p-tau231) and evaluate their associations with cognitive decline in individuals with probable DLB. Design, Setting, and Participants: This multicenter longitudinal cohort study included participants from the European-DLB (E-DLB) Consortium cohort enrolled at 10 centers with harmonized diagnostic procedures from January 1, 2002, to December 31, 2020, with up to 5 years of follow-up. A total of 1122 participants with plasma samples were available. Participants with acute delirium or terminal illness and patients with other previous major psychiatric or neurologic disorders were excluded, leaving a cohort of 987 clinically diagnosed participants with probable DLB (n = 371), Parkinson disease (n = 204), AD (n = 207), as well as healthy controls (HCs) (n = 205). Main Outcomes and Measures: The main outcome was plasma p-tau181 and p-tau231 levels measured with in-house single molecule array assays. The Mini-Mental State Examination (MMSE) was used to measure cognition. Results: Among this cohort of 987 patients (512 men [51.9%]; mean [SD] age, 70.0 [8.8] years), patients with DLB did not differ significantly regarding age, sex, or years of education from those in the AD group, but the DLB group was older than the HC group and included more men than the AD and HC groups. Baseline concentrations of plasma p-tau181 and p-tau231 in patients with DLB were significantly higher than those in the HC group but lower than in the AD group and similar to the Parkinson disease group. Higher plasma concentrations of both p-tau markers were found in a subgroup of patients with DLB with abnormal CSF amyloid-β42 levels compared with those with normal levels (difference in the groups in p-tau181, -3.61 pg/mL; 95% CI, -5.43 to -1.79 pg/mL; P = .049; difference in the groups in p-tau231, -2.51 pg/mL; 95% CI, -3.63 to -1.39 pg/mL; P = .02). There was no difference between p-tau181 level and p-tau231 level across confirmed AD pathologic characteristcs based on reduced Aβ42 level in CSF in individuals with DLB. In DLB, a significant association was found between higher plasma p-tau181 and p-tau231 levels and lower MMSE scores at baseline (for p-tau181, -0.092 MMSE points; 95% CI, -0.12 to -0.06 MMSE points; P = .001; for p-tau231, -0.16 MMSE points; 95% CI, -0.21 to -0.12 MMSE points; P < .001), as well as more rapid MMSE decline over time. Plasma p-tau181 level was associated with a decrease of -0.094 MMSE points per year (95% CI, -0.144 to -0.052 MMSE points; P = .02), whereas plasma p-tau231 level was associated with an annual decrease of -0.130 MMSE points (95% CI, -0.201 to -0.071 MMSE points; P = .02), after adjusting for sex and age. Conclusions and Relevance: This study suggests that plasma p-tau181 and p-tau231 levels may be used as cost-effective and accessible biomarkers to assess cognitive decline in individuals with DLB.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
li完成签到 ,获得积分10
2秒前
科目三的应助被ZeyG采纳,获得10
6秒前
啊唔发布了新的文献求助10
7秒前
Panxy完成签到,获得积分10
7秒前
xx关闭了xx的文献求助
8秒前
9秒前
ding的应助被圈圈采纳,获得10
9秒前
9秒前
10秒前
2026221709发布了新的文献求助10
12秒前
12秒前
清爽的初之完成签到,获得积分10
12秒前
111发布了新的文献求助10
14秒前
15秒前
金箍棒发布了新的文献求助20
15秒前
16秒前
辛勤枫叶完成签到,获得积分10
16秒前
可爱的函函的应助被尊嘟假嘟采纳,获得10
16秒前
斯文败类的应助被尊嘟假嘟采纳,获得10
16秒前
Jasper的应助被尊嘟假嘟采纳,获得10
17秒前
华仔的应助被尊嘟假嘟采纳,获得10
17秒前
今后的应助被尊嘟假嘟采纳,获得10
17秒前
万能图书馆的应助被尊嘟假嘟采纳,获得10
17秒前
JiaYouguo发布了新的文献求助60
17秒前
Lucas的应助被尊嘟假嘟采纳,获得10
17秒前
18秒前
忧虑的灵槐关注了科研通微信公众号
18秒前
飞快的南安完成签到,获得积分10
18秒前
20秒前
笑而不语完成签到 ,获得积分0
21秒前
23秒前
ZeyG发布了新的文献求助10
24秒前
大聪明完成签到,获得积分10
24秒前
24秒前
英俊的铭的应助被科研通管家采纳,获得10
25秒前
Lemonhead的应助被科研通管家采纳,获得100
25秒前
SciGPT的应助被科研通管家采纳,获得10
25秒前
传奇3的应助被科研通管家采纳,获得10
25秒前
完美世界的应助被科研通管家采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184595
求助须知:如何正确求助?哪些是违规求助? 9573554
关于积分的说明 21832227
捐赠科研通 7781812
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480994